Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses checkpoint inhibitors in liver cancer.
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses checkpoint inhibitors in liver cancer.
There is a place for checkpoint inhibitors in liver cancer, says Ghassan, but currently he chooses tyrosine kinase inhibitor (TKI) therapy. Upcoming data with checkpoint inhibitors will read out soon and will affect sequencing, he adds.
Additionally, Abou-Alfa says that there may be potential for chimeric antigen receptor (CAR) T-cell therapy in the treatment of liver cancer, but data are not currently available.
